A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD + adduct

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 28-35

  Mahapatra, Sebabrata ^a   Woolhiser, Lisa K ^a   Lenaerts, Anne J ^a   Johnson, John L ^b   Eisenach, Kathleen D ^c   Joloba, Moses L ^d   Boom, W Henry ^b   Belisle, John T ^a  

^a Department of Ecosystem Science and Sustainability   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^d MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

4 ISONICOTINOYLNICOTINAMIDE; DRUG METABOLITE; ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; NICOTINAMIDE ADENINE DINUCLEOTIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG METABOLISM; DRUG URINE LEVEL; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BIOTRANSFORMATION; CATALASE; CHROMATOGRAPHY, LIQUID; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; ISONIAZID; MASS SPECTROMETRY; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; NAD; OXIDATION-REDUCTION; OXIDOREDUCTASES; TUBERCULOSIS, PULMONARY;

EID: 84455161882     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05486-11     Document Type: Article

References (37)

1. Argyrou A, Vetting MW, Aladegbami B, Blanchard JS. 2006. Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nat. Struct. Mol. Biol. 13:408-413. (Pubitemid 43881580)
2. Banerjee A, et al. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263:227-230. (Pubitemid 24067929)
3. + metabolism in health and disease. Trends Biochem. Sci. 32:12-19.
4. Bender DA, Russell-Jones R. 1979. Isoniazid-induced pellagra despite vitamin-B6 supplementation. Lancet ii:1125-1126. (Pubitemid 10211500)
5. Burke GJ, Hlangabeza T. 1977. Isoniazid-induced pellagra in a patient on vitamin B supplement. S. Afr. Med. J. 51:719. (Pubitemid 8125743)
6. Comaish JS, Cooper M. 1977. Isoniazid-induced pellagra. Arch. Dermatol. 113:986-987.
7. Comaish JS, Felix RH, McGrath H. 1976. Topically applied niacinamide in isoniazid-induced pellagra. Arch. Dermatol. 112:70-72.
8. Darvay A, Basarab T, McGregor JM, Russell-Jones R. 1999. Isoniazid induced pellagra despite pyridoxine supplementation. Clin. Exp. Dermatol. 24:167-169.
9. Delaine T, et al. 2010. Development of isoniazid-NAD truncated adducts embedding a lipophilic fragment as potential bi-substrate InhA inhibitors and antimycobacterial agents. Eur. J. Med. Chem. 45:4554-4561.
10. DiAugustine RP. 1976. Formation in vitro and in vivo of the isonicotinic acid hydrazide analogue of nicotinamide adenine dinucleotide by lung nicotinamide adenine dinucleotide glycohydrolase. Mol. Pharmacol. 12:291-298.
11. Ellard GA, Gammon PT. 1976. Pharmacokinetics of isoniazid metabolism in man. J. Pharmacokinet. Biopharm. 4:83-113. (Pubitemid 8133355)
12. Ellard GA, Gammon PT, Wallace SM. 1972. The determination of isoniazid and its metabolites acetylisoniazid, monoacetylhydrazine, diacetylhydrazine, isonicotinic acid and isonicotinylglycine in serum and urine. Biochem. J. 126:449-458.
13. Gazzaniga F, Stebbins R, Chang SZ, McPeek MA, Brenner C. 2009. Microbial NAD metabolism: lessons from comparative genomics. Microbiol. Mol. Biol. Rev. 73:529-541.
14. Gopinathan KP, Sirsi M, Vaidyanathan CS. 1964. Nicotinamide-adenine dinucleotide glycohydrolase of Mycobacterium tuberculosis H37Rv. Biochem. J. 91:277-282.
15. Gu J, et al. 2009. Cloning and characterization of NAD-dependent protein deacetylase (Rv1151c) from Mycobacterium tuberculosis. Biochemistry 74:743-748.
16. Hillar A, Loewen PC. 1995. Comparison of isoniazid oxidation catalyzed by bacterial catalase-peroxidases and horseradish peroxidase. Arch. Biochem. Biophys. 323:438-446.
17. Johnsson K, Schultz PG. 1994. Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis. J. Am. Chem. Soc. 116:7425-7426. (Pubitemid 24274243)
18. Joloba ML, et al. 2000. Quantitative sputum bacillary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 4:528-536. (Pubitemid 30409169)
19. Lamichhane G, et al. 2003. A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: application to Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 100:7213-7218. (Pubitemid 36706418)
20. Lei BF, Wei CJ, Tu SC. 2000. Action mechanism of antitubercular isoniazid - activation by Mycobacterium tuberculosis KatG, isolation, and characterization of InhA inhibitor. J. Biol. Chem. 275:2520-2526.
21. Lenaerts AJ, et al. 2005. Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother. 49:2294-2301. (Pubitemid 40734457)
22. McLean P, Greenbaum AL, Brown J, Greenslade KR. 1967. Influence of hormones on the nicotinamide nucleotide coenzymes of adipose tissue. Biochem. J. 105:1013-1018.
23. Mdluli K, et al. 1996. Biochemical and genetic data suggest that InhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis. J. Infect. Dis. 174:1085-1090. (Pubitemid 26357474)
24. Meyrick Thomas RH, Rowland Payne CM, Black MM. 1981. Isoniazid-induced pellagra. Br. Med. J. 283:287-288. (Pubitemid 11048223)
25. Nguyen M, Claparols C, Bernadou J, Meunier B. 2001. A fast and efficient metal-mediated oxidation of isoniazid and identification of isoniazid-NAD(H) adducts. Chembiochem 2:877-883. (Pubitemid 33722701)
26. Nguyen M, Quemard A, Broussy S, Bernadou J, Meunier B. 2002. Mn(III) pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:2137-2144. (Pubitemid 34665908)
27. Preziosi P. 2007. Isoniazid: metabolic aspects and toxicological correlates. Curr. Drug Metab. 8:839-851. (Pubitemid 350238914)
28. Rawat R, Whitty A, Tonge PJ. 2003. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc. Natl. Acad. Sci. U. S. A. 100:13881-13886. (Pubitemid 37499160)
29. Reiss PD, Zuurendonk PF, Veech RL. 1984. Measurement of tissue purine, pyrimidine, and other nucleotides by radial compression high-performance liquid chromatography. Anal. Biochem. 140:162-171. (Pubitemid 14093658)
30. Rozwarski DA, Grant GA, Barton DH, Jacobs WR Jr., Sacchettini JC. 1998. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279:98-102. (Pubitemid 28079164)
31. Singh AK, et al. 2010. Mode of binding of the tuberculosis prodrug isoniazid to heme peroxidases: binding studies and crystal structure of bovine lactoperoxidase with isoniazid at 2.7 A resolution. J. Biol. Chem. 285:1569-1576.
32. Snider DE Jr., Farer LS. 1978. Preventive therapy with isoniazid for "inactive" tuberculosis. Chest 73:4-6. (Pubitemid 8271989)
33. Stigliani JL, et al. 2008. Binding of the tautomeric forms of isoniazid-NAD adducts to the active site of the Mycobacterium tuberculosis enoyl-ACP reductase (InhA): a theoretical approach. J. Mol. Graph. Model. 27:536-545.
34. Trouwborst RE, Clement BG, Tebo BM, Glazer BT, Luther GW III. 2006. Soluble Mn(III) in suboxic zones. Science 313:1955-1957. (Pubitemid 44498001)
35. Vilcheze C, Jacobs WR Jr. 2007. The mechanism of isoniazid killing: clarity through the scope of genetics. Annu. Rev. Microbiol. 61:35-50. (Pubitemid 350058198)
36. Wang F, et al. 2010. Mycobacterium tuberculosis dihydrofolate reductase is not a target relevant to the antitubercular activity of isoniazid. Antimicrob. Agents Chemother. 54:3776-3782.
37. World Health Organization. 2010. Global tuberculosis report 2010 (WHO/HTM/TB/2010.7), p 1-2. WHO, Geneva, Switzerland.